Nicotine pharmacokinetics and subjective response among adult smokers using different flavors of on! nicotine pouches compared to combustible cigarettes.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Rensch (2021)
Investigating the DNa methylation profile of e-cigarette use.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Richmond (2021)
Nicotine Exposure by Device Type among adult Electronic Nicotine Delivery System Users in the Population assessment of Tobacco and health Study, 2015-2016.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Rostron (2020)
Neural-hematopoietic-inflammatory axis in nonsmokers, electronic cigarette users, and tobacco smokers.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Ruedisueli (2022)
Pharmacokinetic and pharmacodynamic properties of aerosolized (“vaped”) ThC in adolescent male and female rats.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Ruiz (2021)
Pod-mod vs. conventional e-cigarettes: nicotine chemistry, ph, and health effects.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Shao (2020)
are E-Cigarette Flavors associated with Exposure to Nicotine and Toxicants? Findings from Wave 2 of the Population assessment of Tobacco and health (PaTh) Study.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Smith (2019)
Differences in Exposure to Nicotine, Tobacco-Specific Nitrosamines, and Volatile Organic Compounds among Electronic Cigarette Users, Tobacco Smokers, and Dual Users from Three Countries.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Smith (2020)
Nicotine absorption from e-cigarettes over 12 months.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Soar (2019)
Rapid Brain Nicotine Uptake from Electronic Cigarettes.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Solingapuram (2020)